

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

April 20, 2022

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2020/1_DrSwees_premeeting_announcement.pdf
- II. Roll Call
- III. Review of meeting transcript for January 19, 2022, meeting
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/DURB_meeting_transcript_1-19-22_upd.pdf
- IV. Review of draft meeting summary for January 19, 2022, meeting
- V. Secretary's report
- VI. Old Business
None
- VII. New Business
 - A. Proposed protocol for Hetlioz[®] (tasimelteon)
 - B. Proposed protocol for cysteamine products
 - C. Proposed protocol for Revcovi[®] (elapegademase)
 - D. Proposed protocol for Luxturna[®] (voretigene neparvovec-rzyl)
- VIII. A. Informational Highlights/Reports
 - 1. Gainwell Technologies/NJ HMO 4th Quarter 2021 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
 - FFS top drugs
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Top_Drugs_Report_\(January-2022\).xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Top_Drugs_Report_(January-2022).xlsx)
 - MCO top drugs
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/MCO_Top_Drugs_Report_\(December-2021\).xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/MCO_Top_Drugs_Report_(December-2021).xlsx)
 - FFS – category
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Top_Drugs_by_Category_\(January-2022\).xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Top_Drugs_by_Category_(January-2022).xlsx)

MCO – category

[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/MCO_Top_Drugs_by_Category_\(December-2021\).xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/MCO_Top_Drugs_by_Category_(December-2021).xlsx)

(b) Antiviral drugs by amount paid

[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Antiviral_Drugs_\(January-2022\).xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/FFS_Antiviral_Drugs_(January-2022).xlsx)

B. Medication information:

1. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.

3. New Jersey COVID-19 Information Hub (continuously updated)

<https://covid19.nj.gov/>

4. Know Your Treatment Options for COVID-19 – FDA

<https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19>

IX. Updated Materials:

A. Proposed protocol for Gamifant® (emapalumab-lzsg) – approved January 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/Gamifant_approved_protocol_1-22.pdf

B. Proposed Protocol for Nitisinone products – approved January 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/Nitisinone_products_approved_protocol_1-22.pdf

C. Proposed protocol for Lucemyra® (lofexidine) – approved January 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/4-2022/Lucemyra_approved_protocol_1-22.pdf